BUZZBERGAlpha Score combines three things: realized average return, confidence in the sample size, idea volume, and speaker reputation. Speakers with only a few calls are pulled closer to the platform average; speakers with many evaluated ideas keep more of their own return. Reputation only boosts: 5.0 or lower is neutral, while scores above 5 add weight. Scores are normalized to 0-100; 100 is best.Read the FAQ
1. THE FACT: The speaker states, "I’m bullish on the long term intel story."
2. THE BRIDGE: Despite the short-term disappointments mentioned in tweet [11], the speaker maintains a positive long-term outlook on Intel's fundamental story.
3. THE VERDICT: Bullish on INTC for the long term, despite potential short-term volatility or disappointment.
1. THE FACT: The speaker states, "I’m bullish on the long term intel story."
2. THE BRIDGE: Despite the short-term disappointments mentioned in tweet [11], the speaker maintains a positive long-term outlook on Intel's fundamental story.
3. THE VERDICT: Bullish on INTC for the long term, despite potential short-term volatility or disappointment.
Buy HLIT on the thesis that the shift to persistent AI agents and edge inference will force broadband operators to upgrade networks, benefiting HLIT's cOS platform for increased upstream capacity and lower latency.
Buy HLIT on the thesis that the shift to persistent AI agents and edge inference will force broadband operators to upgrade networks, benefiting HLIT's cOS platform for increased upstream capacity and lower latency.
Buy QCOM as a contrarian bet on edge AI or memory efficiency breakthroughs that could squeeze shorts and re-rate cheap stock, with multi-month horizon.
Buy QCOM as a contrarian bet on edge AI or memory efficiency breakthroughs that could squeeze shorts and re-rate cheap stock, with multi-month horizon.
1. THE FACT: The speaker notes a recurring pattern: "fear of Japanese rates has caused a selloff," and in response, they are "preparing to buy Nvidia" in 2022, 2024, and now 2026.
2. THE BRIDGE: The speaker views selloffs driven by "fear of Japanese rates" as a temporary market overreaction that creates a buying opportunity for NVDA, which has historically recovered.
3. THE VERDICT: Buy NVDA on dips caused by fear of Japanese rates, as this is seen as a recurring buying opportunity.
1. THE FACT: The speaker notes a recurring pattern: "fear of Japanese rates has caused a selloff," and in response, they are "preparing to buy Nvidia" in 2022, 2024, and now 2026.
2. THE BRIDGE: The speaker views selloffs driven by "fear of Japanese rates" as a temporary market overreaction that creates a buying opportunity for NVDA, which has historically recovered.
3. THE VERDICT: Buy NVDA on dips caused by fear of Japanese rates, as this is seen as a recurring buying opportunity.
Buy and hold agentic AI utility names BAND, ATEN, and SAIL; author discloses active long positions and explicitly commits to slow-selling discipline, citing the cycle lesson that large gains (700%+) are not a sufficient exit signal.
Buy and hold agentic AI utility names BAND, ATEN, and SAIL; author discloses active long positions and explicitly commits to slow-selling discipline, citing the cycle lesson that large gains (700%+) are not a sufficient exit signal.
Buy and hold agentic AI utility names BAND, ATEN, and SAIL; author discloses active long positions and explicitly commits to slow-selling discipline, citing the cycle lesson that large gains (700%+) are not a sufficient exit signal.
Buy and hold agentic AI utility names BAND, ATEN, and SAIL; author discloses active long positions and explicitly commits to slow-selling discipline, citing the cycle lesson that large gains (700%+) are not a sufficient exit signal.
Buy RVMD on Phase 3 RASolute 302 data showing daraxonrasib significantly outperformed chemotherapy in metastatic pancreatic cancer; upside extends beyond pancreatic cancer TAM via platform optionality of RAS-targeting across other oncology indications.
Buy RVMD on Phase 3 RASolute 302 data showing daraxonrasib significantly outperformed chemotherapy in metastatic pancreatic cancer; upside extends beyond pancreatic cancer TAM via platform optionality of RAS-targeting across other oncology indications.
Long these Chinese semiconductor names based on Citrini's thematic thesis that they will outperform US peers; catalyst is upcoming updated review this weekend.
Long these Chinese semiconductor names based on Citrini's thematic thesis that they will outperform US peers; catalyst is upcoming updated review this weekend.
Long analog semis in the AI power infrastructure basket as the analog cycle has turned and content per server rises, offering asymmetric upside versus memory/optics/compute re-ratings.
Long analog semis in the AI power infrastructure basket as the analog cycle has turned and content per server rises, offering asymmetric upside versus memory/optics/compute re-ratings.
Long analog semis in the AI power infrastructure basket as the analog cycle has turned and content per server rises, offering asymmetric upside versus memory/optics/compute re-ratings.
Long analog semis in the AI power infrastructure basket as the analog cycle has turned and content per server rises, offering asymmetric upside versus memory/optics/compute re-ratings.
Long analog semis in the AI power infrastructure basket as the analog cycle has turned and content per server rises, offering asymmetric upside versus memory/optics/compute re-ratings.
Long analog semis in the AI power infrastructure basket as the analog cycle has turned and content per server rises, offering asymmetric upside versus memory/optics/compute re-ratings.